Insulin-like growth factors and coronary heart disease

Cardiology in Review

Volumn 13, Issue 1, 2005, Pages 35-39

  Kaplan, Robert C ^a   Strickler, Howard D ^a   Rohan, Thomas E ^a   Muzumdar, Radhika ^a   Brown, David L ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Epidemiology; Etiology

Indexed keywords

BEZAFIBRATE; GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN C;

ACROMEGALY; APOPTOSIS; ARTERY BLOOD FLOW; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CIRCULATION; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; ENDOTHELIUM; EPIDEMIOLOGICAL DATA; EXPERIMENTAL MODEL; GROWTH HORMONE DEFICIENCY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MEDIATOR; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ACUTE DISEASE; AGING; ANIMALS; ARTERIOSCLEROSIS; CELL SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 13444302623     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000134914.10407.40     Document Type: Review

References (49)

1. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res. 2000; 86:125-130.
2. Pfeifer M, Verhovec R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999;84:453-457.
3. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-288.
4. Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am. 1996;25:591-614.
5. Silha JV, Gui Y, Modric T, et al. Overexpression of the acid-labile subunit of the IGF ternary complex in transgenic mice. Endocrinology. 2001;142:4305-4313.
6. Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology. 1991;129: 710-716.
7. Conover CA, Bale LK, Durham SK, et al. Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology. 2000;141: 3098-3103.
8. Boes M, Dake BL, Booth BA, et al. IGF-I and IGFBP-3 transport in the rat heart. Am J Physiol Endocrinol Metab. 2003;284:E237-239.
9. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997;336:633-640.
10. Hunt KJ, Toniolo P, Akhmedkhanov A, et al. Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev. 2002;11:901-905.
11. Tornberg SA, Jakobsson KF, Eklund GA. Stability and validity of a single serum cholesterol measurement in a prospective cohort study. Int J Epidemiol. 1988;17:797-803.
12. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol. 1997;145:970-976.
13. Yu H, Mistry J, Nicar MJ, et al. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin- like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal. 1999;13:166-172.
14. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279: 563-566.
15. Chen JW, Ledet T, Orskov H, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab. 2003;284:E1149-E1155.
16. Goodman-Gruen D, Barrett-Connor E, Rosen C. IGF-1 and ischemic heart disease in older people. J Am Geriatr Soc. 2000;48:860-861.
17. Janssen JA, Stolk RP, Pols HA, et al. Serum total IGF-I, free IGF-1, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998;18:277-282.
18. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001;38:26-32.
19. Reeves I, Abribat T, Laramee P, et al. Age-related serum levels of insulin-like growth factor-I, -II and IGF-binding protein-3 following myocardial infarction. Growth Horm IGF Res. 2000;10:78-84.
20. Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944.
21. Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002;359:1740-1745.
22. Schuler-Luttmann S, Monnig G, Enbergs A, et al. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:E10-15.
23. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol. 1996;77:200-202.
24. Botker HE, Skjaerbaek C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol. 1997;79:961-963.
25. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol. 2000;35:647-654.
26. van den Beld AW, Bots ML, Janssen JA, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157: 25-31.
27. Kimura KD. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science. 2001;292:107-110.
28. Tissenbaum HA, Liu Y, Ruvkun G, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Science. 1997;277: 942-946.
29. Brown-Borg HM, Borg KE, Meliska CJ, et al. Dwarf mice and the ageing process. Nature. 1996;384:33.
30. Anversa P, Reiss K, Kajstura J, et al. Myocardial infarction and the myocyte IGF1 autocrine system. Eur Heart J. 1995;16(suppl N):37-45.
31. Friehs I, Stamm C, Cao-Danh H, et al. Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann Thorac Surg. 2001;72:1650-1656.
32. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100:1991-1999.
33. Lee WL, Chen JW, Ting CT, et al. Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology. 1999;140:4831-4840.
34. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
35. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res. 2001;88:998-1003.
36. Bornfeldt KE, Raines EW, Nakano T, et al. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266-1274.
37. Sidway AN, Hakim FS, Jones BA, et al. Insulin-like growth factor-I binding in injury-induced intimal hyperplasia of rabbit aorta. J Vasc Surg. 1996;23:308-313.
38. Emanuelsson H, Beatt KJ, Bagger JP, et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation. 1995;91:1689-1696.
39. Eriksen UH, Amtorp O, Bagger JP, et al. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J. 1995;130:1-8.
40. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996;347:305-307.
41. Conn KJ, Rich CB, Jensen DE, et al. Insulin-like growth factor-I regulates transcription of the elastin gene through a putative retinoblastoma control element. A role for Sp3 acting as a repressor of elastin gene transcription. J Biol Chem. 1996;271:28853-28860.
42. Krettek A, Sukhova GK, Libby P. Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis. Arterioscler Thromb Vasc Biol. 2003;23:582-587.
43. Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol. 2002;39:90-95.
44. Muniyappa R, Walsh MF, Rangi JS, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61:925-931.
45. Capaldo B, Guardasole V, Pardo F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation. 2001;103:520-524.
46. Wu HY, Jeng YY, Yue CJ, et al. Endothelial-dependent vascular effects of insulin and insulin-like growth factor 1 in the perfused rat mesenteric artery and aortic ring. Diabetes. 1994;43:1027-1032.
47. Tsukahara H, Gordienko DV, Tonshoff B, et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45:598-604.
48. Copeland KC, Nair KS. Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab. 1994;79:230-232.
49. Ferrucci L, Guralnik JM. Inflammation, hormones, and body composition at a crossroad. Am J Med. 2003;115:501-502.